AMLo Biosciences’ Post

The second visual in AMLo Biosciences #MelanomaMay series looks at how melanoma-associated #anxiety can affect family life. Being diagnosed with #melanoma, the most aggressive form of #skincancer, is an extremely emotional experience. Despite the fact that only around 15% of early-stage melanomas will progress into later stage disease, the anxiety around fear of recurrence can be debilitating for some patients. Patients worry about parenting their children, caring for relatives and planning for the future. With our prognostic #biomarker technology, clinicians can identity early-stage melanomas that are at low risk of progression. This information can offer some reassurance to these patients. Find out more: www.amlo-biosciences.com #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers #knowyourskin

This year’s Annual Meeting of the British Association of Dermatologists (BAD) is being held in Manchester on 2-4 July. Jude Kilbee and Jane Meaney will be hosting AMLo Biosciences’ exhibition stand E3, so stop by to find out more about our work with prognostic biomarkers One of our developed technologies identifies early-stage #melanomas at genuine low-risk of metastasis. Our ongoing research is looking at identifying at-risk and high-risk melanomas. Come and chat about how this additional prognostic information can help inform clinical decision making and aid in alleviating some patient anxiety around disease progression. amlo-biosciences.com #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers

We were interested to read in a recent JAMA research letter that following a first #melanoma diagnosis, patients have an almost 9-fold increased risk of developing another primary melanoma compared with the general population. The authors go on to explain that this risk varies across racial and ethnic groups but the highest absolute risk was found in the white population. They conclude that further work is needed to guide population-level monitoring in the future. https://bit.ly/4dTlmIu   Our prognostic test #AMBLor identifies early-stage melanomas that are at low risk of progression. Stratifying patients into low-risk or at-risk means that any further diagnostic procedures and follow-up schedules can be personalised, potentially saving time, resources and helping to alleviate patient anxiety. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers 

AMLo Biosciences were interested to read that #rosacea, the chronic inflammatory skin disease that is often considered just a cosmetic issue, should be noted as a potential indicator of serious conditions. A German-based study is the first to conclusively link rosacea with other comorbidities, including #melanoma. Using global data from a real-world database, the group found that rosacea was associated with an increased risk of malignant melanoma, contradicting earlier studies. Whilst this correlation was true for the Caucasian population, it was not found in the Asian sub-cohort.  https://bit.ly/3RmNJpO www.amlo-biosciences.com #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch    

AMLo Biosciences issued a news release this week announcing that #AMLBLor received its #UKCA mark making it available to NHS and private hospitals. AMBLor is an innovative histopathological biomarker for early-stage #melanoma. It accurately identifies the presence of two prognostic proteins, AMBRA1 and loricrin, in the skin overlying the tumour. The presence of one or both biomarkers is associated with a low risk of progression. This additional prognostic information could help reduce the burden of procedures and appointments on both patients and stretched healthcare resources, and provide a more tailored management approach. Read the full press release: https://bit.ly/479VHJK #dermatology #dermatopathology #histopathology #histology #oncology #skincancer #cancerresearch #biomarkers #prognostics #healthinvestment

It’s interesting to see the growing trend for the use of immunohistochemistry (IHC) to help decision making in melanoma. In a retrospective US study focused on incident cases of in situ or malignant #melanoma in patients 65+ years, 39-68% used IHC. https://bit.ly/43EpVmq But what real difference can IHC make? Penny Lovat of Newcastle University has noted, 'Incorporating a simple, reliable, low-cost assay into routine testing provides additional prognostic information that can help avoid further invasive diagnostic procedures, lengthy follow-up, or unnecessary treatment, whilst vastly reducing the burden on both individual patients and clinical resources.' www.amlo-biosciences.com #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers 

It has been reported that #AI can enhance ‘diagnostic accuracy, trust, and confidence among dermatologists’. However, when physicians make decisions with AI, errors can still occur: We agree that more research is needed to better understand how to identify and avoid human-AI collaboration errors, to meet the full potential of AI-supported decision making. https://bit.ly/3XBPZ0a   AMLo Biosciences are working on both machine learning and #AI applications to further enhance the risk stratification accuracy of our biomarker prognostic #AMBLor that accurately identifies early-stage melanomas at low risk of progression. We believe that practitioner-led AI will bring improvements to healthcare. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers #melanoma

Our take-away from the #AAD24 congress is that melanoma remains a significant health concern. Receiving a diagnosis of #melanoma is a life-changing moment with many patients experiencing overwhelming emotions. What has been missing is an accurate predictor identifying the subset of patients who are at genuinely low-risk of progression. We firmly believe that widespread use of #AMBLor #biomarker technology that reliably stratifies early-stage, low risk melanomas, could make a dramatic impact on melanoma management. Find out more: www.amlo-biosciences.com #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch

Here at AMLo Biosciences we acknowledge how real the fears that accompany a #melanoma diagnosis can be. Anxiety arising from Financial Toxicity (financial distress) for those diagnosed with any cancer can have a significant adverse effect on quality of life that can manifest in many ways including: ·    Poor physical health ·    Poor mental health and depression ·    Social distress ·    Family distress https://bit.ly/49JxxWs We have developed a prognostic test, #AMBLor, to help reduce the anxiety associated with a #melanoma diagnosis. By identifying those at low risk of progression at an early stage, we aim to reduce the physiological and psychological burden and offer some reassurance for what the future may hold. For further information about the benefits of AMBLor, take a look at our website www.amlo-biosciences.com #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers  

AMLo Biosciences were not surprised to read the results of US research investigating travel time to tanning facilities and #melanoma incidence. For every 1-minute increase in travel time, the study found there was a decrease in the incidence of melanoma. Therefore, decreasing access to such facilities has the potential to reduce melanoma rates. This negative association allowed the researchers to identify clusters of melanoma incidence and may help future targeting of interventions and resources to reduce melanoma burden.  https://bit.ly/4fljaLk Remember, there is no safe way to use tanning beds without UV damage to the skin. Be #skinaware #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch